Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TALPHERA, INC.ACRX · Entity 7102 | Chief Legal Officer | February 07, 2017 | February 10, 2017 |
| Vaxcyte, Inc.PCVX · Entity 1164 | General Counsel | August 16, 2021 | August 18, 2021 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Legal Officer | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TALPHERA, INC.
Report date February 07, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2028-02-06 | Direct | 79,500 |
Reported balance
After 2017-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-07 · Grant · Acquired 79,500 · Balance 79,500 F1: Issued pursuant to the 2011 Equity Incentive Plan. F2: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. F3: 100% Acceleration upon Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to the 2011 Equity Incentive Plan.
F2: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.
F3: 100% Acceleration upon Change of Control.
Vaxcyte, Inc.
Report date August 16, 2021 · Filed August 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,125 |
Ending reported balance
After 2021-08-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-08-16 · Exercise / conversion · Acquired 2,500 · Balance 5,625 Row 2 · 2021-08-16 · Sale · Disposed 2,500 · Balance 3,125 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2029-03-20 | Direct | 187,468 |
Reported balance
After 2021-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-16 · Exercise / conversion · Disposed 2,500 · Balance 187,468 F2: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.
Vera Therapeutics, Inc.
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 42,403 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 42,403 · Balance 42,403 F1: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.73 · Expires 2036-03-22 | Direct | 56,850 |
Reported balance
After 2026-03-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-23 · Grant · Acquired 56,850 · Balance 56,850 F2: 12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
F2: 12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 25, 2026 19:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 56,850 | $0.00 Strike: $40.73 | $0.00 |
DisclosureSEC source: 0001614568-26-000008 · form4-03252026_110324.xml · derivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,850 Underlying: Class A Common Stock · 56,850 shares Expires 2036-03-22 F2 · derivative.exercise_date: 12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 19:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 42,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001614568-26-000008 · form4-03252026_110324.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,403 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-052311 · doc4.xml · derivative · entry 3 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,468 Underlying: Common Stock · 2,500 shares Expires 2029-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $26.00 | $65,000.00 |
DisclosureSEC source: 0001209191-21-052311 · doc4.xml · nonDerivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:02 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $2.03 | $5,075.00 |
DisclosureSEC source: 0001209191-21-052311 · doc4.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-051631 · doc4.xml · derivative · entry 3 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,968 Underlying: Common Stock · 10,000 shares Expires 2029-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $26.00 | $260,000.00 |
DisclosureSEC source: 0001209191-21-051631 · doc4.xml · nonDerivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $2.03 | $20,300.00 |
DisclosureSEC source: 0001209191-21-051631 · doc4.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,563 shares acquired under the Employment Stock Purchase Plan on May 17, 2021. Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 93,340 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001209191-21-025762 · doc4.xml · derivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,340 Underlying: Common Stock · 93,340 shares Expires 2031-03-31 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-021392 · doc4.xml · derivative · entry 4 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,968 Underlying: Common Stock · 2,500 shares Expires 2029-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,487 | $27.49 | $40,877.63 |
DisclosureSEC source: 0001209191-21-021392 · doc4.xml · nonDerivative · entry 3 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.355 to $27.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,013 | $27.01 | $27,361.13 |
DisclosureSEC source: 0001209191-21-021392 · doc4.xml · nonDerivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.28 to $27.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $2.03 | $5,075.00 |
DisclosureSEC source: 0001209191-21-021392 · doc4.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-011322 · doc4.xml · derivative · entry 3 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,468 Underlying: Common Stock · 2,500 shares Expires 2029-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $26.95 | $67,375.00 |
DisclosureSEC source: 0001209191-21-011322 · doc4.xml · nonDerivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.52 to $27.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $2.03 | $5,075.00 |
DisclosureSEC source: 0001209191-21-011322 · doc4.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 23:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-004102 · doc4.xml · derivative · entry 3 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,968 Underlying: Common Stock · 2,500 shares Expires 2029-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 23:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $26.00 | $65,000.00 |
DisclosureSEC source: 0001209191-21-004102 · doc4.xml · nonDerivative · entry 2 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 23:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $2.03 | $5,075.00 |
DisclosureSEC source: 0001209191-21-004102 · doc4.xml · nonDerivative · entry 1 Wright-Mitchell Jane · CIK 0001614568 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,562 shares acquired under the Employee Stock Purchase Plan on November 17, 2020. Read SEC document |
| February 07, 2017 Filed Feb 10, 2017 01:54 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock (Right to Buy) · Derivative | 79,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001437749-17-002063 · rdgdoc.xml · derivative · entry 1 Mitchell Jane Wright · CIK 0001614568 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2028-02-06 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. F3 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.